These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 27627749)

  • 21. Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study.
    Iovino C; Au A; Chhablani J; Parameswarappa DC; Rasheed MA; Cennamo G; Cennamo G; Montorio D; Ho AC; Xu D; Querques G; Borrelli E; Sacconi R; Pichi F; Woodstock E; Sadda SR; Corradetti G; Boon CJF; van Dijk EHC; Loewenstein A; Zur D; Yoshimi S; Freund KB; Peiretti E; Sarraf D
    Am J Ophthalmol; 2020 Sep; 217():104-113. PubMed ID: 32360342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
    Rajesh B; Agrawal H; Peguda HK; Chhablani J
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
    Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
    Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
    Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Manabe S; Shiragami C; Hirooka K; Izumibata S; Tsujikawa A; Shiraga F
    Am J Ophthalmol; 2015 Apr; 159(4):644-51. PubMed ID: 25595669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy.
    Gawęcki M; Jaszczuk-Maciejewska A; Jurska-Jaśko A; Kneba M; Grzybowski A
    BMC Ophthalmol; 2019 Jul; 19(1):160. PubMed ID: 31345183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Am J Ophthalmol; 2015 Jul; 160(1):72-84.e1. PubMed ID: 25887629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience.
    Petkovsek DS; Cherfan DG; Conti FF; Hom GL; Ehlers JP; Babiuch AS; Rachitskaya AV; Kaiser PK; Schachat AP; Srivastava SK; Sharma S; Singh RP
    Br J Ophthalmol; 2020 Feb; 104(2):182-187. PubMed ID: 31079056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
    Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
    Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multimodal Imaging in Fibrinous Central Serous Chorioretinopathy Compared with Exudative Maculopathy.
    Lyu Y; Li X; Gong Y
    Ophthalmologica; 2020; 243(5):360-369. PubMed ID: 32008002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and clinical correlates of focal choroidal excavation in eyes with age-related macular degeneration, polypoidal choroidal vasculopathy and central serous chorioretinopathy.
    Lim FP; Wong CW; Loh BK; Chan CM; Yeo I; Lee SY; Mathur R; Wong D; Wong TY; Cheung CM
    Br J Ophthalmol; 2016 Jul; 100(7):918-923. PubMed ID: 26504178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Furuta M; Sekiryu T
    Retina; 2011 Oct; 31(9):1921-7. PubMed ID: 21878850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
    Yavuz S; Balsak S; Karahan M; Dursun B
    J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in choroidal thickness after systemic administration of high-dose corticosteroids: a pilot study.
    Han JM; Hwang JM; Kim JS; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):440-5. PubMed ID: 24370828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pachychoroid neovasculopathy: aspect on optical coherence tomography angiography.
    Azar G; Wolff B; Mauget-Faÿsse M; Rispoli M; Savastano MC; Lumbroso B
    Acta Ophthalmol; 2017 Jun; 95(4):421-427. PubMed ID: 27597633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year follow-up of choroidal and macular thickness in acute non-treated central serous chorioretinopathy.
    Orduña-Azcona J; Pérez-Fernández E; Modamio L; De Manuel-Triantafilo S; Rodríguez-Hernández CF; Gili P
    Clin Exp Optom; 2023 Jan; 106(1):47-55. PubMed ID: 35157808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.
    Shulman S; Goldenberg D; Schwartz R; Habot-Wilner Z; Barak A; Ehrlich N; Loewenstein A; Goldstein M
    Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):15-22. PubMed ID: 25794988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.